AMD's AI Ambition: Instinct MI350 Price Soars 70%
AMD hikes Instinct MI350 AI chip price to $25K, indicating strong demand and a fiercer challenge to NVIDIA. AMD is supplying OpenAI/Tesla.

AMD hikes Instinct MI350 AI chip price to $25K, indicating strong demand and a fiercer challenge to NVIDIA. AMD is supplying OpenAI/Tesla.
BioNTech's new "smart bomb" cancer drug, trastuzumab pamirtecan, excelled in trials for HER2+ breast cancer, beating an older therapy. This marks BioNTech's first major oncology success and offers a promising new option for patients, globally.
CERo's AML drug, CER-1236, received FDA Fast Track & Orphan Drug status and is in a Phase 1/1b trial. CERo Therapeutics faces a Nasdaq delisting challenge due to low stockholders' equity, but has appealed and plans to raise funds.
Cretostimogene, a new bladder cancer treatment, shows durable 24-month complete responses (41.8%) in high-risk patients unresponsive to BCG. It has a good safety profile and offers bladder-sparing potential, with approval submission planned.